Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option when other breast cancer treatments have failed.

Tyverb is indicated in combination with capecitabine for advanced or metastatic breast cancer in patients whose tumours overexpress ErbB2 (HER2). Patients should have progressive disease following prior therapy that included anthracyclines and taxanes and trastuzumab in the metastatic setting.

Lapatinib has a 'conditional licence' which is valid for 1 year and requires GSK to provide further trial data. A conditional licence is granted when a drug fulfils an unmet medical need and the benefit to public health outweighs the risk that additional data are still required.

View Tyverb drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more